Gerresheimer AG: JPMorgan Sees 124% Price Potential - Adjusted Mid-term Targets Were Expected and Have Turned Out Better Than Feared!

Gerresheimer AG (i.) is regarded as a leading partner in the pharmaceutical, biotech, and cosmetics industries. The company is currently navigating a challenging market environment but shows a significant revenue and earnings jump in the first half of 2025 thanks to strategic acquisitions such as Bormioli Pharma. While temporary market influences were felt in the operating business, the company's long-term growth trajectory remains intact, supported by a focus on high-margin solutions and robust demand in key areas. The company offers a comprehensive...